Jul 2026· European Journal of Preventive Cardiology· 1 citation
Medicine
TL;DR
KM stages were associated with a stepwise increase in risk of CVD and all-cause mortality, with important sex-specific differences observed particularly for all-cause mortality, and support the relevance of CKM staging for cardiovascular risk stratification and prevention in the general population.
Abstract
Aims
To examine the associations between cardiovascular-kidney-metabolic syndrome (CKM) stages and the risk of cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD), and all-cause mortality (ACM), stratified by sex.
Methods
AND
Results
Using a population-based cohort, CoLaus|PsyCoLaus, we categorized participants into CKM stages: 0 (no CKM factors), 1 (excess/dysfunctional adiposity), 2 (metabolic risk factors and/moderate- to high-risk CKD), 3 (very high predicted CVD risk per SCORE2/very high-risk CKD), and 4 (clinical CVD). Associations were assessed using generalized ordered logistic regression, Cox proportional hazards models, and population attributable fractions (PAFs). Among 5,752 participants (53.2% women; mean age: women 53.1 ± 10.7, men 52.3 ± 10.7 years), 580 CVD events (381 ASCVD), and 723 deaths occurred over 14.3 years. CKM stage distribution differed by sex (men vs women): 0 (9.9 vs 26.1%), 1 (13.3 vs 13.7%), 2 (62.6 vs 56.8%), 3 (9.4 vs 1.7%), 4 (4.8 vs 1.7%). Risk of CVD and ASCVD rose with higher CKM stage (vs stage 0), with HRs of 5.16 (95% CI, 2.61-10.19) and 3.82 (1.76-8.27) for stage 3 in men, compared with 1.92 (0.91-4.04) and 1.95 (0.79-4.81) in women. For all-cause mortality, risk peaked at stage 3 in women (3.43 [1.92-6.10]) and at stage 4 in men (2.42 [1.27-4.64]). Incremental PAFs peaked at stage 2.
Conclusion
CKM stages were associated with a stepwise increase in risk of CVD and all-cause mortality, with important sex-specific differences observed particularly for all-cause mortality. These findings support the relevance of CKM staging for cardiovascular risk stratification and prevention in the general population.
Advanced CKM syndrome is associated with long-term mortality outcomes including all-cause and cardiovascular death, underscoring the importance of early screening and staging of CKM syndrome to prevent disease progression and reduce mortality risk.
Lan-Lan Li, D. T. Lui, C. Fong et al.· Journal of the American Hear...· 0 citations
Aims Stage 3 in cardiovascular–kidney–metabolic (CKM) syndrome, defined as subclinical cardiovascular disease (CVD), diagnosis often relies on risk equivalents (very high‐risk CKD or high 10‐year CVD risk) due to the limited accessibility of diagnostic tools. A critical unanswered question is whether these two risk‐equ...
Xiangyuan Wang, Meng-Ge Yang, Qunwei Ma et al.· International Journal of End...· 0 citations
Cardiovascular-kidney-metabolic (CKM) syndrome integrates metabolic abnormalities, chronic kidney disease, and cardiovascular disease (CVD), with stages 0–3 representing a critical window for primary prevention. Whether the Chinese visceral adiposity index (CVAI) adds predictive value for CVD in this population r...
Long Feng, Geng Yang, He-Song Zeng et al.· Cardiovascular Diabetology· 0 citations
In T2DM, LDL-C burden and variability jointly identified patients at greater risk, especially for MI and cardiovascular mortality, especially in younger adults or longer-duration diabetes subgroups.
Dae-Jeong Koo, J. Park, Kyungdo Han et al.· Diabetes, obesity and metabo...· 0 citations
BACKGROUND
Steatotic liver disease (SLD) is closely associated with cardiometabolic factors, but whether the cardiovascular-kidney-metabolic (CKM) stage stratifies risk for major adverse cardiovascular events (MACEs) and liver-related events (LREs) across SLD subtypes remains unclear.
METHODS
In the UK Biobank study,...
Qiong-Yue Fan, Li-You Lian, Tian-Yi Xia et al.· i Medicina· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.